Earnings Report /

EIPICO: Solid revenue growth; bottom-line pressured by R&D and financing expenses

  • Modest growth in retail pharma market caps performance

  • Solid revenue growth, GPM expands on faster-growing revenues than COGS

  • Bottom line pressured by R&D costs and higher financing expenses

Mariam Wael
Al Ahly Pharos Securities Brokerage
7 November 2021